Baralgin M - instructions for use, analogs, reviews and release forms (tablets 500 mg, injections in ampoules) an anesthetic for the treatment of headaches and dental pain, colic and menstruation in adults, children and pregnancy. Composition

In this article, you can read the instructions for using the drug Baralgin M. Comments of visitors of the site - consumers of this medication, as well as opinions of doctors of specialists on the use of Baralgina M in their practice are presented. A big request is to actively add their feedback on the drug: the medicine helped or did not help get rid of the disease, which were observed complications and side effects, possibly not declared by the manufacturer in the annotation. Analogues of Baralgin M in the presence of existing structural analogues.Use for the treatment of headaches and dental pain, with colic and menstruation in adults, children, as well as during pregnancy and lactation. Composition of the preparation.

Baralgin M refers to non-narcotic agents, derivatives of pyrazolone. It has analgesic, antipyretic and weak anti-inflammatory action.

By the mechanism of action is practically no different from other non-steroidal analgesic drugs.

Composition

Metamizol sodium + auxiliary substances.

Pharmacokinetics

Metamizole is absorbed well and quickly in the digestive tract. After oral administration metamizole is completely metabolized with the formation of active 4-N-methylaminoantipyrine. The association of the active metabolite with the blood plasma proteins is 50-60%. It is mainly excreted by the kidneys. In therapeutic doses penetrates into breast milk.

Indications

• pain syndrome of mild and moderate intensity (headache and toothache, neuralgia, pain with radiculitis, osteochondrosis, arthritis, menalgia)
• spasms of smooth muscles (renal colic, biliary colic, intestinal colic)
• feverish conditions with infectious and inflammatory diseases (as part of combination therapy).

Forms of release

Tablets 500 mg.

Solution for intravenous and intramuscular injection (injections in ampoules for injection).

Instructions for use and dosage

Pills

A single dose for adults and adolescents over 15 years is 500 mg (1 tablet). The maximum single dose can reach 1000 mg (2 tablets). Unless otherwise prescribed, a single dose can be taken up to 2-3 times per day. The maximum daily dose is 3000 mg (6 tablets).

Duration of admission is no more than 5 days when prescribed as an anesthetic and no more than 3 days as an antipyretic agent.

Tablets should be washed down with a sufficient amount of water. An increase in the daily dose of the drug or the duration of treatment is possible only under the supervision of a physician.

Ampoules

Adults and adolescents 15 years and older: 1-2 ml of 50% (500 mg / 1 ml) solution of Baralgin M (intramuscular or intravenous) is recommended as a single dose, the daily dose can be up to 4 ml of injection solution (not more than 2 g), divided into 2-3 reception. The maximum single dose can be 1 g (2 ml of 50% solution).

Children and newborns: Baralgin M should not be given to newborns until the age of 3 months or with a body weight of less than 5 kg.

Children Baralgin M is given in a dose of 50-100 mg per 10 kg of body weight (0.1-0.2 ml of 50% solution).

A single dose can be prescribed up to 2-3 times a day. Before administration, the solution is recommended to be heated to body temperature.

For children aged 3-12 months, the introduction is carried out only in / m (body weight of the child from 5 to 9 kg).

With too rapid administration of the drug, a critical drop in blood pressure and shock can occur. In / in the introduction should be done slowly (the rate of administration is not more than 1 ml (500 mg metamizole) per minute) in the supine position, with control over the blood pressure, pulse and respiration rate.

Since there is a concern that the drop in blood pressure of non-allergic genesis is dose-dependent, the amount of Baralgina M solution greater than 2 ml (1 g) should be administered with extreme caution.

Side effect

• urticaria, including, on the conjunctiva and mucous membranes of the nasopharynx;
• angioedema;
• malignant exudative erythema (Stevens-Johnson syndrome);
• toxic epidermal necrolysis (Lyell's syndrome);
• bronchospastic syndrome;
• anaphylactic shock;
• leukopenia, rarely agranulocytosis and thrombocytopenia of immune genesis;
• impaired renal function;
• oliguria;
• anuria;
• very rarely the development of acute interstitial nephritis;
• staining urine in red (due to the release of the metabolite - rubric acid);
• with the / m introduction, infiltrates are possible at the injection site;
• possibly lowering blood pressure;
• disturbance of the heart rhythm.

Contraindications

• hepatic porphyria;
• congenital deficiency of glucose-6-phosphate dehydrogenase;
• 1 and 3 trimester of pregnancy;
• bronchial asthma (including induced by the use of acetylsalicylic acid, salicylates or other non-steroidal anti-inflammatory drugs);
• diseases accompanied by bronchospasm;
• the development of anaphylactoid reactions (hives, rhinitis, edema) in response to salicylates, paracetamol, diclofenac, ibuprofen, indomethacin, naproxen;
• marked violations of the liver and kidneys;
• expressed violations of hematopoiesis (agranulocytosis, cytoplastic and infectious neutropenia);
• contraindicated in newborns under 3 months of age or at a body weight of less than 5 kg;
• increased sensitivity to metamizole - the active substance, as well as other components of the drug, or other pyrazolones (isopropylaminofenazole, propiphenazone, phenazone or phenylbutazone).

Application in pregnancy and lactation

During the 1st and 3rd trimester of pregnancy, you can not take Baralgin M. From the fourth to the sixth months of pregnancy, the reception of Baralgina M should be carried out under strict medical conditions.

After taking Baralgin M, breastfeeding should be stopped for 48 hours.

Use in children

Baralgin M should not be taken to newborn children under 3 months of age or with a body weight of less than 5 kg.

Children Baralgin M is given in a dose of 50-100 mg per 10 kg of body weight (0.1-0.2 ml of 50% solution).

A single dose can be prescribed up to 2-3 times a day. Before administration, the solution is recommended to be heated to body temperature.

For children aged 3-12 months, the introduction is only intramuscular (body weight of the child from 5 to 9 kg). Infants at the age of 3 to 12 months are contraindicated intravenous route of administration.

special instructions

In the treatment of patients receiving cytotoxic drugs, Baralgin should be administered only under medical supervision.

During pregnancy, especially in the first 3 months and the last 3 months, you can not use any non-steroidal anti-inflammatory drugs.

The increased risk of hypersensitivity reactions to metamizole sodium is available:

• in patients with bronchial asthma, especially with concomitant polyps in
• the area of ​​the nasal sinuses;
• in patients with chronic urticaria;
• in patients with alcohol intolerance;
• in patients with intolerance to dyes (eg, tartrazine) or to preservatives (eg benzoate).

With prolonged use, it is necessary to monitor the picture of peripheral blood. Against the background of taking metamizole sodium, the development of agranulocytosis is possible, therefore, if an unmotivated rise in temperature, chills, sore throats, difficulty swallowing, stomatitis, erosive-ulcerative lesions of the oral cavity, vaginitis or proctitis is required, immediate withdrawal of the drug is necessary.

It is inadmissible to use the drug to relieve acute pain in the abdomen (until finding out the cause).

In patients with impaired liver and kidney function, it is recommended to avoid metamizole sodium at high dosages.

When intramuscular injection should use a long needle.

Drug Interactions

Simultaneous reception of alcohol and Baralgina mutually affects their effects. When used in conjunction with cyclosporine, there may be a decrease in the concentration of cyclosporin in the blood.The simultaneous use of metamizole with other non-narcotic analgesics may lead to a mutual enhancement of toxic effects.

Tricyclic antidepressants, oral contraceptives, Allopurinol disrupt metamizole metabolism in the liver and increase its toxicity.

Barbiturates, phenylbutazone and other inducers of microsomal liver enzymes weaken the effect of Baralgin.

Sedatives and tranquilizers increase the analgesic effect of the drug. Simultaneous use with chlorpromazine or other phenothiazine derivatives can lead to the development of severe hyperthermia.

Radiocontrast agents, colloidal blood substitutes and penicillin should not be used during metamizole treatment.

Metamizole, displacing from the bond with protein oral hypoglycemic drugs, indirect anticoagulants, glucocorticosteroid agents and indomethacin, increases their activity.

Myelotoxic drugs increase the manifestation of hematotoxicity of the drug. Thiamazole and sarcolysin increase the risk of developing leukopenia. The effect is enhanced by codeine, histamine H2 blockers and propranolol.

Because of the high likelihood of pharmaceutical incompatibility, metamizole should not be mixed with other drugs in the same syringe.

Analogues of the drug Baralgin

Structural analogs for the active substance:

• Analgin;
• Metamizol sodium;
• Optalgin;
• Spasdulzin for children.

Analogues on the curative effect (remedies for killing of renal colic):

• Analgin;
• Aprofen;
• Aspizol;
• I took it;
• Bralangin;
• Buscopan;
• Voltaren;
• Galidor;
• Dexalgin;
• Dibazol;
• Diqlovit;
• Diclomelan;
• Diclonac;
• Dicloran;
• Diclofenac;
• Drotaverine;
• Maxigan;
• Metacin;
• Naklofen;
• But the spine;
• But the forte;
• Novigan;
• Papaverine;
• Pape;
• Platyphylline;
• Promedol;
• Prosidol;
• Rapent Rapid;
• Remidon;
• Spasgan;
• Spazmalgon;
• Spazmoveralgin Neo;
• Spazmol;
• Spasmonet;
• Spacock;
• Spaskuprel;
• Yunispaz.

Similar medicines:

Other medicines: